Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467063 | 0.91 | TBXAS1 (0.52) | TBXAS1HRH1CCR3SMN1; SMN2SLC6A2 | |
| SCHEMBL7088226 | 0.88 | TBXAS1 (0.50) | TBXAS1HRH1CCR3 | |
| SCHEMBL7388461 | 0.85 | TBXAS1 (0.56) | TBXAS1HRH1CCR3 | |
| SCHEMBL535547 | 0.85 | TBXAS1 (0.49) | TBXAS1SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20552139 | 0.84 | TBXAS1 (0.55) | TBXAS1HRH1CCR3SMN1; SMN2SLC6A2 | |
| SCHEMBL13684905 | 0.84 | TBXAS1 (0.55) | TBXAS1HRH1CCR3SMN1; SMN2SLC6A2 | |
| SCHEMBL3105876 | 0.82 | TBXAS1 (0.54) | TBXAS1HRH1CCR3SMN1; SMN2SLC6A2 | |
| SCHEMBL687723 | 0.82 | TBXAS1 (0.54) | TBXAS1HRH1CCR3SMN1; SMN2SLC6A2 | |
| SCHEMBL688706 | 0.82 | TBXAS1 (0.54) | TBXAS1HRH1CCR3SMN1; SMN2 | |
| SCHEMBL2536496 | 0.82 | KMT2A (0.54) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893087-B2 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL, S.A. (ES) | 2011-02-22 | — | — | US | claimed |
| US-7879874-B2 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL, S.A. (ES) | 2011-02-01 | — | — | US | claimed |
| US-20100234332-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | PRAT QUINONES MARIA | 2010-09-16 | — | — | US | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-20070129398-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2007-06-07 | — | — | US | claimed |
| US-20070129420-A1 | New pyrrolidinium derivatives | ALMIRALL PRODESFARMA SA | 2007-06-07 | — | — | US | claimed |
| US-20070105897-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2007-05-10 | — | — | US | claimed |
| US-7192978-B2 | Pyrrolidinium derivatives | ALMIRALL PRODESFARMA AG (CH) | 2007-03-20 | — | — | US | claimed |
| US-7122558-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA AG (CH) | 2006-10-17 | — | — | US | claimed |
| EP-1353919-B1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2006-07-26 | — | — | EP | claimed |
| US-20050282875-A1 | Pyrrolidinium derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2005-12-22 | — | — | US | claimed |
| EP-1497284-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | Almirall Prodesfarma AG (CH) | 2005-01-19 | — | — | EP | claimed |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2004-04-15 | — | — | US | claimed |
| WO-2003087094-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | ALMIRALL PRODESFARMA AG (CH) | 2003-10-23 | — | — | WO | claimed |
| EP-1353919-A2 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2003-10-22 | — | — | EP | claimed |
| WO-2002053564-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-11 | — | — | WO | claimed |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| CN-1143361-A | Phenylacetic acid derivatives, their preparation and intermediates, and compositions containing them | BASF AG (DE) | 1997-02-19 | — | — | CN | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282875-A1 | Pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | TBXAS1 2551/4885HRH1 187/4885CCR3 671/4885 |
| US-20070129420-A1 | New pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | TBXAS1 2237/4885HRH1 206/4885CCR3 713/4885 |
| US-20070129398-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | NR0B1, NR2C2, NR1I3 | TBXAS1 2167/4885HRH1 867/4885CCR3 338/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | TBXAS1 617/4885HRH1 63/4885CCR3 748/4885 |
| US-20100234332-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NR0B1, NR4A1, NR0B2 | TBXAS1 2243/4885HRH1 794/4885CCR3 339/4885 |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | CYP11B1, CYP3A7, CBR1 | TBXAS1 2045/4885HRH1 765/4885CCR3 653/4885 |
| US-20070105897-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | NR0B1, NR4A1, NR0B2 | TBXAS1 2070/4885HRH1 919/4885CCR3 329/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | TBXAS1 1522/4885HRH1 68/4885CCR3 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.